On November 3, the 2022 China Biotechnology Innovation Conference, co-hosted by the China Biotechnology Development Center and the Suzhou Municipal People's Government, was held online, and the conference also released the 2022 China Biomedical Industrial Park Development Competitiveness Evaluation and Analysis Report, among the 211 biomedical industrial parks participating in the competitiveness ranking in the country, Jiangsu has a total of 14 parks in the top 50 and 6 parks in the top 20, including Suzhou Industrial Park, Taizhou Pharmaceutical High-tech Industrial Development Zone, and Nanjing Biomedical Valley , Nanjing Jiangning High-tech Industrial Development Zone, Wuzhong Economic Development Zone, Lianyungang High-tech Industrial Development Zone, showing the growth
of Jiangsu's biomedical industry.
The report shows that biomedicine has become an important pillar industry for the development of parks in various places, and the proportion of the total output value of biomedicine in the sample parks to the total industrial volume of the park has increased year by year, and has exceeded 22%
in 2021.
Among them, Suzhou Industrial Park has strong comprehensive competitiveness, it is reported that at present, the park is accelerating the development of biomedical innovation, up to now, the park has gathered more than 2,000 biomedical-related enterprises, a total of 24 biopharmaceutical companies listed, gathered 6 (quasi) unicorn enterprises at all levels, 96 gazelle (cultivation) enterprises at all levels, and in 2021, the park will add 4 listed first-class new drugs and 5 listed innovative medical device products, accounting for 15% of the national total.
Among the 9 domestic PD-1 monoclonal antibody tumor drugs that have been marketed in China, 3 are manufactured
in the park.
Taizhou Pharmaceutical High-tech Industrial Development Zone has always adhered to the development direction of internationalization and modernization, with planning and construction as the leader, investment and intelligence as the fundamental, independent innovation as the driving force, and comprehensive supporting as the support, attracting many domestic and foreign scientists and entrepreneurs to invest and start businesses
.
At present, a number of domestic and foreign pharmaceutical research and development institutions such as the Hamner Research Institute, Texas Medical Center, and China Pharmaceutical University have gathered in the zone, and a number of pharmaceutical production and service-oriented enterprises have settled down, and a large number of pharmaceutical blockbuster innovation achievements have been successfully declared
.
Nanjing Biomedical Valley is a Nanjing biomedical industry base and high-end biomedical R&D zone that Nanjing has clearly focused on building in terms of industrial layout, and is also the core bearing area
of the "Gene City" construction in the development blueprint of "two cities and one center" of the national Jiangbei New Area.
Relying on the national major new drug creation and major scientific and technological achievements transfer pilot demonstration base, the park focuses on the development of gene industry, immune cell therapy, CAR-T cell therapy, biopharmaceuticals, pharmaceutical research and development, medical devices and other fields
。 At present, the park has settled more than 700 enterprises, forming an industrial structure based on R&D and innovation, gathering a number of leading innovative enterprises such as Simcere TECO, Luye Pharmaceutical, Jianyou Biochemical, PharmaBlock Technology, Shihe Gene, including 61 enterprises above designated size, 3 enterprises with revenue of more than 1 billion yuan and 21 enterprises with revenue of more than 100 million yuan in 2019; It has independently cultivated 5 listed companies and 66 national high-tech enterprises
.
Nanjing Jiangning High-tech Industrial Development Zone adheres to the concept of "sowing seeds, raising small seedlings, and moving large trees", takes "China Gene Valley" - Nanjing Life Science and Technology Town as the core carrier, focuses on the development of gene technology, new drug creation, medical equipment and other fields, and builds a biomedical industry cluster, and innovation achievements continue to appear
。 Among them, the world's first anti-AIDS class 1.
1 long-acting drug independently developed by Frontier Biologics - "AboVetai" has entered the industrialization stage; Nanjing Legend Biologics' tumor-specific T cell therapy (CAR-T) was the first to enter the confirmatory phase clinical trial; The new drug for the treatment of class 1.
1 kidney cancer independently developed by Tianyin Jianhua is about to start clinical trials
.
More than 500 industry leading enterprises
have settled in the industrial zone, such as GenScript Biotechnology, a large-scale gene synthesis service provider, Hengrui Pharmaceutical, "Pharmaceutical First Brother" Hengrui Pharmaceutical, and Zhengda Tianqing, a national liver medicine technology head enterprise.
Since 2001, Wuzhong Economic Development Zone has been named "National Torch Pharmaceutical Characteristic Industrial Base", with a sound and developed industrial system, rich innovation factors, and strong
R&D and innovation capabilities.
In recent years, the district has focused on the three major fields of high-end biomedicine, high-end medical equipment and service outsourcing, and vigorously developed precision medicine, smart medical care and other health fields, and has gathered nearly 400 enterprises
such as WuXi AppTec, OKon Vision and Tengmai Pharmaceutical.
In the first three quarters of 2022, the scale of the biomedical industry in the Economic Development Zone reached 17.
463 billion yuan, a year-on-year increase of 11.
9%.
Lianyungang High-tech Industrial Development Zone aims to target the 100 billion yuan park, and supports pharmaceutical innovation and research and development, achievement transformation, MAH new business formats, industrial growth, ecological construction, etc.
, forming a policy highland
with great competitiveness and excellent attraction.
In order to further promote investment attraction, the Municipal Development Zone has launched the establishment of a new pharmaceutical industry fund to help biomedicine, high-end medical equipment and other projects settle in the park; 3 projects such as Hechen Pharmaceutical were completed and put into production, 4 projects such as the International Pharmaceutical Innovation Industrial Park started construction, and 5 industrial projects such as Nuotai R&D Center and biological agents were signed and landed
.
At present, the core area has settled in 26 pharmaceutical projects such as Osa Pharmaceutical with a total investment of 2 billion yuan
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
